70 results about "Oxcarbazepine" patented technology

A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.

Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and / or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.

The present invention provides a pharmaceutical composition comprising oxcarbazepine and at least one pharmaceutical excipient, wherein the oxcarbazepine in the composition has a broad particle size distribution and an enhanced oxcarbazepine dissolution rate. The broad particle size distribution of oxcarbazepine in the pharmaceutical composition is preferably a multi-modal oxcarbazepine particle size distribution.

Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and / or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.

A process for preparing (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz / b,f / azepine-5-carboxamide or (R)-(−)-10,11-dihydro-10-hydroxy-5H-dibenz / b,f / azepine-5-carboxamide, by reduction of oxcarbazepine in the presence of a catalyst and a hydride source is disclosed. The catalyst is prepared from a combination of [RuX2(L)]2 wherein X is chlorine, bromine or iodine, and L is an aryl or aryl-aliphatic ligand, with a ligand of formula (A) or formula (B):wherein R1 is chosen from C1-6 alkoxy and C1-6 alkyl, n is a number from 0 to 5, and when n is a number from 2 to 5, R1 can be the same or different, and R2 is alkyl, substituted alkyl, aryl, substituted aryl, alkaryl or substituted alkaryl. The hydride source is either NR3R4R5 and formic acid, [R3R4R5NH][OOCH] and optionally formic acid, or [M][OOCH]x and formic acid, wherein R3, R4 and R5 are C1-6 alkyl, M is an alkali metal or alkaline earth metal and x is 1 or 2. A pH from 6.5 to 8 is maintained during the process.

The present invention provides a pharmaceutical composition comprising oxcarbazepine .and at least one pharmaceutical excipient, wherein the oxcarbazepine in the composition has a broad particle size distribution. The broad particle size distribution of oxcarbazepine in the pharmaceutical composition is preferably a multi-modal oxcarbazepine particle size distribution, preferably with an enhanced oxcarbazepine dissolution rate.

The invention discloses an oxcarbazepine dry suspension and a preparation method thereof. The oxcarbazepine dry suspension is prepared from oxcarbazepine, microcrystalline cellulose, xanthan gum, solubilizer, filler, a conventional amount of flavoring agent and aromatizer. According to the oxcarbazepine dry suspension prepared by adopting a spray drying method, time can be saved, the defects of agglomeration, high particle cracking rate, non-uniform shape and grain diameters and the like of a wet-process granulation method can be overcome, and the prepared granules are uniform, high in dissolving speed, relatively excellent in liquidity and excellent in taste, the production efficiency can be improved, and the cost for the dry suspension can be reduced. The oxcarbazepine dry suspension is suitable for industrial production.

A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.

Oral once a day dosage forms comprising oxcarbazepine are disclosed.

A pharmaceutical dosage form comprising a mixture of a therapeutically effective amount of oxcarbazepine having median particle size ranging from about 15 μm to about 26 μm and one or more hydrophilic polymers, said mixture being formed by subjecting a suspension comprising said oxcarbazepine and a hydrophilic polymer in a solvent, to mixing in a homogenizer, optionally removing the solvent and converting the said mixture into a dosage form.

The invention belongs to the technical field of biology, and provides a reagent for detecting human leukocyte antigen B site 1502 genotype (HLA-B*1502), application of the reagent in preparation of akit for guiding administration of antiepileptic drugs such as carbamazepine, oxcarbazepine, phenytoin and lamotrigine, a corresponding kit and a detection method of the kit. According to the HLA-B*1502 genotyping, three groups of MIX reaction solutions are detected by adopting a PCR-fluorescent probe method, and target nucleic acid molecules are circularly amplified through an amplification reaction, so that a fluorescence generation group is indirectly combined with an amplified target nucleotide sequence; the amount of fluorescence generated by the fluorescence generation group is determined, and the existence of the target nucleotide is determined. The detection reagent comprises a nucleic acid amplification system of three groups of MIX reaction solutions, wherein the nucleic acid amplification system comprises an upstream primer 1 and a downstream primer 1 which can be combined with target nucleotide, and an upstream primer 2 and a downstream primer 2 which can be combined with the target nucleotide; and three groups of probes 1 and probes 4 of a fluorescence detection system matched with the nucleic acid amplification system.